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This white paper provides updated ITC recommendations on transporters that are important
in drug development following the 3rd ITC workshop. New additions include prospective
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evaluation of OCT1 and retrospective evaluation of OATP2B1 because of their important
roles in drug absorption, disposition and effects. For the first time, the ITC underscores
importance of transporters involved in drug-induced vitamin deficiency (THTR2) and those
involved in the disposition of biomarkers of organ function (OAT2 and bile acid
transporters).

Author Manuscript

The third International Transporter Consortium (ITC) transporter workshop was held with
the purpose of updating recommendations on transporters in drug development. A key goal
was to discuss transporters of emerging clinical relevance, and reach consensus on whether
the clinical evidence supports incorporation of these transporters into the practice of drug
development. Authors of this manuscript formed a working group to reach consensus on
emerging drug transporters of clinical relevance. Previously, ITC recommendations were
largely focused on transporters important in mediating drug-drug interactions (DDIs) or
associated with liver toxicity. In this white paper, ITC recommendations extend beyond
transporters important in DDIs to include transporters that are potentially important in
mediating drug-induced vitamin deficiencies and those that are involved in the disposition of
biomarkers associated with drug-induced organ toxicities. Updated ITC recommendations
on transporters in drug development are summarized in this revised ITC transporter figure
(Figure 1). Below, new recommendations are summarized under each transporter along with
the evidence supporting those recommendations.
I.

New Recommendations for Transporters as Mediators of Clinical DDIs

Author Manuscript

In this section, evidence is presented for several transporters, as mediators of clinical DDIs
in the liver and intestine. In particular, recent clinical studies support the roles of the hepatic
transporter, OCT1, in mediating clinically important DDIs. The possible involvement of the
organic anion transporting polypeptide transporter, OATP2B1, in mediating both intestinal
and hepatic DDIs, needs to be considered to understand observed DDIs that cannot be
attributed to more common mechanisms (e.g., intestinal P-gp/BCRP, hepatic
OATP1B1/1B3). Brief comments on other transporters, for which clinical evidence is sparse,
are included.

Author Manuscript

Organic Cation Transporter 1 (OCT1)—Human OCT1 (SLC22A1) is mainly
expressed in the liver, localized on the sinusoidal side of hepatocytes. Hepatic OCT1 was
discussed in the 2010 ITC white paper (1), and evaluation of inhibitors of this transporter
was first recommended in European Medicines Agency’s 2010 draft DDI guideline and
remains in their final DDI guideline for understanding potential alterations in metformin
distribution to the liver, the primary site of metformin pharmacology. Practical
implementation of this recommendation has been challenging, because systemic exposure is
the major endpoint of DDI studies in drug development. Notably, OCT1 is not a determinant
of metformin plasma levels, because this drug is eliminated almost exclusively by the kidney
(2). Metformin clinical DDI studies, to date, have been primarily triggered by in vitro
studies of investigational drugs’ interactions with the renal transporters, OCT2, MATE1, and
MATE2-K, and have focused on changes in systemic metformin exposure, an endpoint that
could be inadequate to inform rational metformin dose adjustment in DDIs (3–6). For
example, selective impairment of OCT1 can reduce hepatic metformin exposure and
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subsequently its anti-hyperglycemic effects, with no apparent changes in systemic
pharmacokinetics (6, 7). Furthermore, nonspecific inhibition of OCTs can reduce the renal
clearance of metformin through OCT2 inhibition, while simultaneously reducing the hepatic
uptake of the drug (through OCT1 inhibition); thus resulting in little net change in hepatic
drug exposure and drug response despite increased systemic exposure as demonstrated
directly in Oct1/2-knockout mice (4). Many OCT/MATE inhibitors are nonspecific for renal
and hepatic metformin transporters, and may alter metformin hepatic distribution and
pharmacodynamics, in addition to renal clearance and systemic pharmacokinetics (8; also
see UCSF-FDA TransPortal http://transportal.compbio.ucsf.edu/). As such, metformin DDI
studies may require pharmacodynamic endpoints (e.g. oral glucose tolerance test) to
understand the true effects of concomitant drugs on metformin pharmacodynamics (3, 4, 6;
metformin clinical DDI study design commentary in this issue). OCT1 inhibitory potential is
critical, in addition to inhibitory potential to OCT2/MATE, to understand whether the
pharmacologic effect of metformin may be altered in the presence of a DDI.
OCT1 inhibition is important to consider for metformin dose adjustments in DDI studies that
are conducted for drugs that modulate metformin renal elimination. However, for reasons
outlined above, metformin is not a sensitive pharmacokinetic probe for OCT1 inhibition. As
detailed below, recent clinical studies identified several OCT1-substrate drugs whose
systemic exposure is sensitive to OCT1 modulation and may be considered as OCT1
systemic probe substrates. Collectively these studies demonstrated that OCT1 can act as the
rate-determining step in hepatic drug clearance of these drugs in a manner conceptually
analogous to hepatic OATPs.

Author Manuscript
Author Manuscript

Recent clinical evidence from pharmacogenetic studies supports hepatic OCT1 as a potential
target for systemic DDIs with notable pharmacokinetic and pharmacodynamic consequences
(see accompanying white paper of clinically-relevant transporter polymorphisms in this
issue of CPT). For example, the OCT1-substrate fenoterol, a narrow therapeutic index beta2
agonist, exhibited a 2-fold elevated systemic exposure in homozygous carriers of OCT1 null
alleles, which elicited clinically concerning 1.5-fold and 3.4-fold greater increases in heart
rate and blood glucose, respectively (9). Similarly, the active O-desmethyl metabolite of
tramadol, which is a substrate of OCT1, exhibited a 2-fold greater exposure, resulting in
enhanced opioid pharmacodynamic activity in healthy subjects, and in clinical practice,
decreased drug self-administration for postoperative pain (10, 11). Further, OCT1 reduced
function polymorphisms were associated with greater systemic exposure (2–4-fold) and
enhanced efficacy (up to 10-fold reduction in vomiting) of the serotonin receptor (5-HT3)
antagonists, ondansetron and tropisetron in over 200 patients (12). In people harboring
OCT1 reduced function polymorphisms, the systemic exposure of the antimigraine
medication, sumatriptan, was increased 2-fold (13). OCT1 reduced function polymorphisms
have been associated with the disposition and pharmacologic effects of the opioid,
morphine; however, these effects are inconsistent between studies and may be confounded
by oral administration of the prodrug versus parenteral administration of morphine directly
(14). DDIs with specific and strong inhibitors may phenocopy PK and possible PD changes
of these OCT1-substrate drugs associated with genetic polymorphisms, and as such, studies
with genetic polymorphisms provide clinical support for OCT1 in mediating DDIs.

Clin Pharmacol Ther. Author manuscript; available in PMC 2021 June 17.
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Based on clinical evidence, evaluation of substrate and inhibition potential for OCT1 is
recommended during drug development. As a hepatic uptake transporter, existing OATP
substrate and inhibitor decision trees can be extended to OCT1 (Figure 2). Note the cut-off
values shown in Figure 2 are consistent with OATP decision trees proposed in the 2017 FDA
in vitro DDI draft guidance, and these may change based on future data. The conduct of in
vitro studies is generally preferred for the clinically-relevant substrate-inhibitor pairs that
will be studied in the clinic; therefore, choice of the substrate to use in assays will depend on
concomitant medications that are most relevant for the new molecular entity (NME) under
study and, if warranted based on decision tree analysis, would be the subject of a subsequent
clinical DDI study. For example, for NMEs used in cancer patients, the sponsor may wish to
consider interactions with 5-HT3 receptor antagonists that appear to be sensitive substrates
based on pharmacogenomics studies discussed above. For drugs predicted to be OCT1
substrates in vivo, as noted, there are no available specific clinical inhibitors of the
transporter. In this case, the high prevalence of homozygous carriers of OCT1 null alleles
(e.g. up to 9% of Caucasians) enables the use of pharmacogenetic studies as a substitute for
a traditional DDI evaluation. Alternatively, a DDI study can be conducted with a nonspecific
OCT1 inhibitor with careful consideration of the effects that inhibition of other pathways
may have on the victim NME.

Author Manuscript

Organic Anion Transporting Polypeptide 2B1 (OATP2B1)—OATP2B1 (SLCO2B1)
exhibits broad tissue expression relative to OATP1B1/1B3 (15). Particularly, OATP2B1 is
the main intestinal OATP isoform (16, 17) and is responsible for DDIs previously attributed
to OATP1A2 (18). Figure 1 shows OATP2B1 as an intestinal apical uptake mechanism,
although apical/basolateral localization in enterocytes remains controversial (19, 20).
Additionally, recent proteomic data indicate that OATP2B1 has similar expression as
OATP1B3 in the liver (21–23), suggesting that its importance in hepatic uptake may have
been underestimated.

Author Manuscript

OATP2B1 has broad substrate specificity, transporting many clinically used drugs, including
atorvastatin and rosuvastatin (15, 24). Detailed analysis of the transport kinetics of
OATP2B1 revealed low- and high-affinity binding sites (25). These binding sites show
distinct Km and Vmax values for typical probe substrates, such as estrone-3-sulfate,
pravastatin, and fexofenadine; likewise, many inhibitors bind preferentially to either the
high- or low-affinity binding site (18, 25). OATP2B1 exhibits pH-dependent transport (26),
which can be clinically relevant in the intestine. Therefore, in addition to standard in vitro
studies at neutral pH, mechanistic evaluation at acidic conditions (e.g. pH 5.5) could
potentially improve in vitro to in vivo extrapolation. Several polymorphisms of OATP2B1
have been described (27). SLCO2B1*3 (c.1457C>T) is the most studied variant, but clinical
relevance is controversial, even for the same substrate drug [e.g., fexofenadine (15)].
Drugs such as the tyrosine kinase inhibitors gefitinib and erlotinib (28), and natural
products, such as naringin and hesperidin in fruit juice (29) are potent inhibitors of
OATP2B1. However, to date, known inhibitors are not specific to OATP2B1 and may
interact with other transporters and drug metabolizing enzymes.

Clin Pharmacol Ther. Author manuscript; available in PMC 2021 June 17.
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In vivo evidence in support of intestinal OATP2B1 as a mediator of DDIs comes largely
from drug-fruit juice interactions. In particular, the Cmax and AUC of several OATP2B1
substrates (including fexofenadine, aliskiren, and celiprolol) were decreased 1.5- to 2-fold
by grapefruit, apple, and orange juice (15, 30–32). Inhibition of intestinal OATP2B1 can
decrease systemic exposure of OATP2B1 substrate drugs without increasing the terminal
half-life. Recent studies showed that ronacaleret, an inhibitor of OATP2B1, decreased
rosuvastain plasma exposure by 50% without altering its terminal half-life (33).

Author Manuscript

Hepatic OATP2B1 may play an important role in drug clearance. However, many OATP2B1
substrates and inhibitors interact with other hepatic transporters and a clear clinical example
of a hepatic OATP2B1 DDI remains elusive (34). For example, asunaprevir, a potent
inhibitor of OATP1B1 and OATP2B1, increased the plasma AUC of rosuvastatin 1.9-fold
(35). In addition to OATP1B1, the asunaprevir/rosuvastatin DDI appears to require
additional consideration of the role of hepatic OATP2B1 for mechanistic explanation. The
relative contribution of OATP2B1 to overall hepatic uptake merits assessment when this
process cannot be otherwise explained.
In summary, OATP2B1 can play a role in intestinal absorption and hepatic clearance of
drugs. Present clinical evidence is insufficient to recommend prospective evaluation of
OATP2B1 in drug development. As an emerging transporter, the role of OATP2B1 should be
explored based on evidence of in vivo transport in the intestine or liver that cannot be
attributed to more common mechanisms (e.g., intestinal P-gp/BCRP, hepatic
OATP1B1/1B3). Intestinal OATP2B1 should be considered as a mechanistic explanation of
DDIs or drug-fruit juice interactions upon observation of apparently decreased absorption of
the substrate drug.

Author Manuscript
Author Manuscript

Organic Anion Transporting Polypeptide 4C1 (OATP4C1)—Human OATP4C1
(SLCO4C1) is localized to the basolateral membrane of the renal proximal tubule (36).
Substrates of OATP4C1 include digoxin, ouabain, and sitagliptin (37). To-date, the
contribution of OATP4C1 to renal elimination of drugs and DDIs has not been well
established beyond tubular secretion of digoxin (38). OATP4C1 has been challenging to
study due to inconsistent ability to attain functional expression in vitro. A recent OATP4C1
in vitro inhibition screening of 53 drugs only identified ritonavir as a clinically-relevant
inhibitor (39). An unexpected DDI between bupropion and digoxin was reported, where
bupropion increased renal clearance of digoxin by 80% (40). Activation of OATP4C1mediated digoxin tubular secretion by bupropion and its metabolites was proposed as the
mechanistic explanation based on in vitro studies (41). Overall, the clinical significance of
OATP4C1 is not well established, and therefore, no recommendations can be made for drug
development at present.
Organic Anion Transporting Polypeptide 1A2 (OATP1A2)—OATP1A2 (SLCO1A2)
is expressed in the brain (42). Notably OATP1A2 is not expressed in enterocytes, despite
initial reports misattributing intestinal OATP transport to OATP1A2. Although not present in
hepatocytes, cholangiocytes lining the bile ducts express OATP1A2 (43). OATP1A2
transports opioid agonists and hydrophilic antimigraine tryptans (42, 44). There is no direct
clinical evidence to link OATP1A2 to enhanced drug entry into the central nervous system
Clin Pharmacol Ther. Author manuscript; available in PMC 2021 June 17.
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(CNS), but knockout mice lacking the murine ortholog suggest this to be the case (45). To
date, there is no clear evidence for clinical DDIs due to brain OATP1A2 inhibition, and
successful targeting of OATP1A2 for CNS drug delivery has yet to be demonstrated. As
such, no recommendations can be made for drug development.
II. New Recommendations for Transporters as Mediators of Biomarker Disposition and
Drug-Vitamin Interactions
In this section, evidence is presented for the organic anion transporter, OAT2, as a mediator
of the disposition of creatinine, and for the thiamine transporter, THTR2, as a mediator of
drug-induced vitamin deficiency in certain populations. Finally, an update is presented on
key bile acid transporters.

Author Manuscript

Organic Anion Transporter 2 (OAT2)—Considerably less attention has been given to
the clinical significance of OAT2 (SLC22A7) relative to its SLC22A counterparts, OAT1/3
(SLC22A6/8) and OCT2 (SLC22A2). Nevertheless, OAT2 has a broad substrate specificity
and is highly expressed in the liver and kidney making it a likely candidate to be a mediator
of clinically relevant DDIs. Particularly intriguing is that OAT2 is the only SLC22A member
highly expressed in the liver with a bias towards anionic substrates. While suffering from
some contradictory findings (46), the main reason OAT2 has not been routinely studied
during the drug development is likely due to the lack of an established role as the molecular
mechanism for clinically significant effects. Although creatinine tubular secretion has been
accepted to be mediated by OCT2 and MATE1/2-K (47), recent studies suggest that OAT2
may be an important contributor to creatinine uptake into the renal proximal tubule (48).
OAT2 therefore has the potential to play an important role in the determination of creatinine
clearance, a commonly used clinical biomarker of renal function.

Author Manuscript

Substrates of OAT2 include structurally diverse physiologic metabolites, signaling
molecules, and drugs. Notably, OAT2 is the most efficient SLC transporter identified to date
for acyclic guanosine nucleoside analogs (acyclovir, ganciclovir and penciclovir) (46, 49–
52), cyclic GMP (46, 48, 49, 53), creatinine (46, 48), and diclofenac (52). OAT2 may play a
role in the hepatic clearance of tolbutamide (54).

Author Manuscript

Recently, in vitro studies have identified OAT2 as the most efficient transporter of creatinine,
approximately 40-fold more efficient than OCT2 (46, 48). Further, the protein expression of
OAT2 in the kidney is within 10-fold of OCT2 expression (55, 56). Taken together, these
data suggest that OAT2 may contribute to the active tubular secretion of creatinine. Indeed,
OAT2 demonstrated predictive utility for clinically changes in serum creatinine with the
experimental Janus Kinase 1 inhibitor, itacitinib (57). Inhibition of OAT2 has also been
suggested to play a role in the serum creatinine elevations observed with indomethacin (46).
However, a study of creatinine excursion mechanisms for 15 drugs suggested that clinical
OAT2 inhibition may be uncommon (58).
Because there is no selective in vivo inhibitor of OAT2, it has been difficult to truly establish
the in vivo role of OAT2 in creatinine disposition. While the broad assessment of OAT2
transport and inhibition for drug candidates cannot be recommended at this time, it is a
promising candidate for future mechanistic, pharmacogenomic, and pharmacologic research.
Clin Pharmacol Ther. Author manuscript; available in PMC 2021 June 17.
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Thiamine Transporter 2 (THTR2)—The thiamine transporters (THTR) 1 (SLC19A2)
and 2 (SLC19A3) are responsible for the oral absorption and tissue distribution of thiamine
(vitamin B1). They are expressed in many organs and important physiologic barriers
including the intestine, blood-brain barrier (BBB) and the kidney proximal tubule (59–61).
While THTR2 is localized on the apical side of enterocytes, and kidney proximal tubules,
the localization of THTR1 is mainly on the basolateral side (59–61). The tissue distribution
and localization makes THTRs potentially important in thiamine intestinal absorption, brain
penetration, and renal reabsorption. THTRs have been thought of as highly selective for
thiamine until recent studies demonstrated interactions of THTRs with commonly prescribed
drugs including metform and trimethoprim and suggested potentially clinically relevant
consequences due to their inhibition by the drug candidate fedratinib (62–64).

Author Manuscript
Author Manuscript

Fedratinib, a Janus Kinase 2 inhibitor, was terminated in phase 3 due to the observation of
neurological adverse events consistent with Wernicke’s encephalopathy (WE) in 8 out of
approximately 600 patients (65). The WE reported with fedratinib use may have been due to
thiamine deficiency (TD), and were ameliorated in at least one patient upon thiamine
supplementation (65). Fedratinib, which shares a common moiety of 4-aminopyrimidine
with thiamine, is a potent inhibitor of THTR2 but not THTR1, and may have interfered with
the oral absorption of thiamine resulting in TD (62). Subsequent studies have identified
several inhibitors of THTRs (63, 64). In particular, the commonly prescribed antibiotic
trimethoprim, which has been associated with TD (66), was found to potently inhibit both
THTR1 and THTR2 at clinically relevant concentrations (63). In addition to the
identification of inhibitors, several drugs have now been identified to be substrates for
THTRs. While fedratinib is a substrate of THTR2 only, trimethoprim is transported by both
THTR1 and THTR2 (63). Although more limited in scope, some substrate overlap has been
observed between THTR2 and other xenobiotic cationic transporters, such as OCT1, OCT2,
MATE1 and MATE2-K. For example prototypical OCT/MATE substrates, metformin, 1methyl-4-phenylpyridinium (MPP+), and famotidine are also transported by THTR2 (64).
Inhibition of THTR2 may have significant impact on thiamine intestinal absorption and
renal reabsorption resulting in TD. However, in addition to THTR2 inhibition, many other
factors including malnutrition, reduced gastrointestinal absorption due to gastric bypass
surgery, prolonged vomiting or diarrhea and chronic alcohol use can cause TD (67). In
addition, many reported cases of drug-induced TD, which ultimately caused WE, were due
to interruption of the thiamine metabolism pathway. For example, tolazamide, a glucose
lowering drug used for the treatment of type 2 diabetes, and isofamide, a chemotherapeutic
agent, have been associated with WE likely caused by their inhibition of thiamine
conversion to thiamine pyrophosphate (68) (69).

Author Manuscript

While many drug-induced TD mechanisms are related to thiamine metabolism, either
directly or indirectly, cases that involve the inhibition of THTR2 resulting in disruption of
thiamine absorption are rather sparse. Although both the [I2]/IC50 and [I1]/IC50 values of
fedratinib for THTR2 and trimethoprim for both THTR1 and THTR2 exceed the cutoff for a
clinical DDI study (i.e., [I2]/IC50 > 10 and [I1]/IC50 > 1.25, where I2 is the intestinal
maximal concentration [dose/250 mL] and I1 is the unbound systemic Cmax), WE has been
observed only with fedratinib treatment. Fedratinib was tested in patients suffering from
Clin Pharmacol Ther. Author manuscript; available in PMC 2021 June 17.
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myelofibrosis, a rare cancer of the bone marrow, while trimethoprim is often used for
treating bladder and urinary tract infections. Therefore, certain patients who are more
vulnerable to vitamin deficiency due to impaired absorption and malnutrition may be more
prone to develop WE than other disease populations following treatment with drugs which
can affect thiamine absorption and distribution. For example, thiamine deficiency has been
reported to be common in the elderly, individuals who abuse alcohol, and in patients who
have undergone bariatric surgery (70, 71). Duration of treatment with a THTR2-inhibitor
drug also is a likely risk factor for TD. In addition, a recent study reported a high rate of
thiamine deficiency in patients with myeloproliferative disorders including an increased
incidence of WE (72) perhaps making this population more sensitive to an inhibitor of
thiamine transport like fedratinib. Therefore, monitoring thiamine concentrations in those
vulnerable patient populations during the treatment with THTR2 inhibitors may help
identify patients at increased risk, and therefore, prevent the onset of drug-induced WE.

Author Manuscript

The incidence of drug-induced vitamin deficiencies may be underappreciated. Factors
affecting the observation of effects on nutrients include the lack of specific monitoring and
that severe clinical events may only manifest in sensitive populations with underlying
vitamin deficiency. THTR2 is important in the absorption and the distribution of thiamine, as
well as various drugs and xenobiotics. Overall, assessing drug interactions with THTR2 in
vitro may aid drug developers in predicting which drugs should be carefully monitored in
susceptible populations for drug-induced thiamine deficiency.

Author Manuscript

Hepatic Bile Acid Transporters—Several hepatic transporters contribute to the
disposition of bile acids, and drug interactions involving some of these transporters may
cause cholestasis and liver injury. In addition to bile acids, phosphatidylcholine and
cholesterol also are important constituents of bile. Phosphatidylcholine forms mixed
micelles with cholesterol and bile acids, protecting bile ducts from toxic bile acids. This
section briefly highlights the key hepatobiliary transporters.

Author Manuscript

Biliary excretion of bile acids is predominantly mediated by BSEP (ABCB11), and a
separate white paper dedicated to BSEP inhibition as a mechanism of drug-induced liver
injury (DILI) is published in this issue of CPT. Clinically, rare mutations that result in
farnesoid X receptor (FXR) deficiency and undetectable BSEP expression can cause rapidly
progressive cholestatic liver injury (73). Although BSEP inhibition has been linked to
intrahepatic accumulation of bile acids, which can trigger clinical cholestasis and may lead
to DILI, it is difficult to prospectively link in vitro inhibition of BSEP with clinical
hepatotoxicity. In addition to BSEP, other hepatic uptake and efflux transporters contribute
to bile acid hepatobiliary disposition. Sodium taurocholate co-transporting polypeptide
(NTCP), a solute carrier protein (SLC10A1) expressed on the basolateral membrane of
hepatocytes, is primarily responsible for hepatic uptake of bile acids in humans. Many BSEP
inhibitors can also inhibit NTCP-/OATP-mediated hepatic uptake of bile acids (74), which
may result in increased systemic concentrations of bile acids. This overlap in bile acid
uptake/efflux inhibition may serve as a protective mechanism to prevent potentially toxic
accumulation of bile acids in the liver (75).
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Multidrug resistance proteins 3 and 4 (MRP3, MRP4) are ATP-dependent efflux pumps
localized to the sinusoidal membrane that mediate the transport of substrates from the
hepatocyte into blood. MRP3 (ABCC3) and MRP4 (ABCC4) are induced under cholestatic
conditions, leading to the hypothesis that these transporters can serve as a compensatory
mechanism to alleviate increases in intracellular bile acid concentrations when biliary
excretion is impaired (76, 77). Increases in liver bile acids and liver toxicity were observed
in bile duct ligated Mrp4-knockout mice, but not Mrp3-knockout mice (78, 79). Direct
human translation of data obtained from pre-clinical bile acid disposition studies can be
challenging due to species differences in the bile acid pool, the relative contribution of
various mechanisms to overall bile acid hepatobiliary disposition, and regulation of those
mechanisms (76, 80). Several groups have attempted to assess whether MRP inhibition in
addition to BSEP inhibition increases DILI predictability; however, this resulted in
conflicting conclusions (81–83). In addition to bile acids, MRP2, MRP3, and MRP4 are
important determinants of hepatobiliary disposition of polar drug metabolites (e.g.
glucuronide conjugates), which can contribute to overall victim and perpetrator DDI
potential (84).

Author Manuscript

The organic solute transporter alpha/beta (OSTα/β), which consists of two gene products
encoded by SLC51A and SLC51B, is a bidirectional transporter expressed on the sinusoidal
membrane of human hepatocytes, cholangiocytes and enterocytes (85). Heterodimerization
of the two subunits and movement of the complex to the basolateral membrane is required
for OSTα/β to transport substrates by facilitated diffusion (86). OSTα/β substrates include
bile acids, sulfate conjugates of steroid hormones, and some drugs (85, 87). Hepatic
expression of OSTα and OSTβ is significantly increased in obstructive cholestasis (88) and
primary biliary cirrhosis (89), a response that is dependent on regulation by FXR. Adaptive
upregulation of OSTα/β may protect the liver from hepatotoxic bile acids that accumulate in
cholestatic conditions (90). Recent studies revealed that troglitazone sulfate, a potent BSEP
inhibitor, also inhibits taurocholate transport by OSTα/β (Malinen in press 2018). OSTα/β
is an emerging compensatory basolateral efflux transporter that functions much like a
“safety-valve” to protect the liver from toxic concentrations of bile acids. Inhibition of
OSTα/β is a potential, but understudied, mechanism that may contribute to bile acidmediated DILI.
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Multidrug resistance-associated protein 2 (MRP2, ABCC2) mediates the biliary excretion of
glucuronide and sulfate conjugates of bile acids (e.g., sulfated tauro- or glycolithocholate),
endogenous compounds (e.g., bilirubin glucuronides), and xenobiotics. Dubin–Johnson
syndrome, genetic deficiency of MRP2, is characterized by hyperbilirubinaemia. Although
total serum bile acid concentrations are unaffected in Dubin-Johnson patients (91),
hepatocyte and systemic concentrations of individual bile acid species may be altered.
Inhibition of MRP2 may result in hepatocellular accumulation of toxic metabolites, which
may contribute to DILI (92). Studies (93) suggest that genetic variations in MRP2 may
increase susceptibility to herb- and drug-induced liver injury. Alterations in MRP2
expression or function may impact the hepatobiliary disposition of bile acids and
hepatotoxic drugs, and could be a contributing factor in DILI.
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Biliary secretion of phosphatidylcholine is mediated by multidrug resistance protein 3
(MDR3, ABCB4) (94). Mice lacking Mdr2, the mouse ortholog of MDR3, exhibit impaired
biliary secretion of phosphatidylcholine and develop hepatobiliary disease (95). In humans,
genetic polymorphisms resulting in MDR3 deficiency lead to cholestatic disorders (96, 97).
Inhibitory effects of drugs on MDR3 have not been extensively investigated, but several
studies support the potential role of MDR3 inhibition in DILI. Itraconazole, which induced
cholestatic liver injury in patients, inhibits MDR3 (98). Screening of 125 drugs
demonstrated that MDR3 clinical inhibition potency may help differentiate hepatotoxic
drugs and non-hepatotoxic drugs (99). In addition, combined analysis of BSEP and MDR3
inhibition data showed that 9 compounds potently inhibited both MDR3 and BSEP (IC50 <
20 μM), all of which were classified as drugs with the highest DILI incidence (99).
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As reviewed in this section, the physiology of bile acid disposition is complex with
involvement of multiple hepatic transporters in addition to BSEP (ABCB11). Moreover, bile
acids undergo extensive enterohepatic recirculation and are metabolized by enzymes in
hepatocytes, intestinal epithelial cells, and by the gut microbiome. The first step in bile acid
re-absorption is mediated by intestinal apical sodium-dependent bile transporter (ASBT,
a.k.a. IBAT), which is not specifically discussed, as it is not a mechanism of cholestasis, but
whose inhibition may warrant consideration upon observation of impaired bile acid
absorption. Hepatic bile acid levels are regulated through the by farnesoid X receptor
through FXR-SHP and FXR-FGF19 pathways, which control multiple adaptation
mechanisms (e.g., decrease in CYP7A1, the rate-limiting step in bile acid synthesis,
induction of sinusoidal efflux transporters, induction of conjugating enzymes and BSEP)
(100, 101). Systematic understanding of a drug’s effects on multiple mechanisms involved in
bile acid homeostasis, beyond direct BSEP inhibition, should be considered for mechanistic
understanding of altered bile acid disposition.
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III.

Concluding remarks

Author Manuscript

Clinical evidence has emerged to justify evaluation of hepatic OCT1 in drug development in
addition to renal transporters OCT2 and MATEs. The proposed evaluation approach for
OCT1 substrates and inhibitors follows principles established for hepatic OATP1B1 and
OATP1B3 (Figure 2), although specific cut-off values necessitate further study and
refinement. Both intestinal and hepatic drug uptake via OATP2B1 should be evaluated
retrospectively in instances of DDIs, drug-food interactions, or disposition otherwise
unexplained by more common mechanisms. Evidence to justify the evaluation of brain
OATP1A2 and renal OATP4C1 with a high level of concern from a DDI perspective is
lacking. THTR2 may be relevant in the context of pre-existing thiamine deficiency, and
therefore, should be considered for drugs used in sensitive populations or when evidence of
drug-induced thiamine deficiency is observed. The manuscript highlights the emerging
importance of OAT2 as a mechanism of creatinine renal secretion, but relevance to drug
development is not sufficiently well established to support specific recommendations.
Transporters involved in bile acid disposition are not specifically recommended for
evaluation with a high level of concern from a DDI perspective, but may be considered in
cholestasis/DILI.
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Figure 1.

Author Manuscript

Transporters proposed for evaluation during drug development in the intestine (a), liver (b),
kidney (c), and brain (d). The transporters previously recommended for evaluation by the
ITC are marked with red circles; transporters previously recommended for retrospective
mechanistic explanation of clinical observations are marked with yellow circles. New
transporters were highlighted on the basis of broad clinical relevance to drug interactions.
OCT1 (green circle) is proposed for evaluation during drug development both for transport
of substrates and inhibitory potential. Retrospective study of OATP2B1 (yellow square) is
warranted in limited specific instances of DDIs or disposition otherwise unexplained by
more common mechanisms. THTRs are new transporters added to the figure; however, drug
inhibition of this transporter is likely relevant in the context of pre-existing thiamine
deficiency and, therefore, should only be considered for drugs used chronically in sensitive
populations or when evidence of drug-induced thiamine deficiency is observed. Symbols for
the other discussed transporters (OATP1A2, OATP4C1, OAT2, ASBT [a.k.a. IBAT], OSTα/
β, NTCP, MDR3) remain as dark blue circles, because evidence is lacking for specific drug
development recommendations.
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Figure 2.

Proposed addition of OCT1 to hepatic OATP substrate (a) and inhibitor (b) decision trees.
Note the cut-off values are consistent with OATP decision trees in the 2017 FDA in vitro
DDI draft guidance. Cut-off values may change based on future data, so the emphasis is
placed not on any specific threshold, but on the concept that OCT1 be considered in a
manner analogous to hepatic OATPs.
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